During the study, patients will be assigned to one of the three treatment groups. They will receive pembrolizumab through a vein every three weeks, while the experimental medicines will be injected directly into accessible tumors on the skin or under the skin every four weeks. Treatment will continue for up to two years or until the cancer gets worse, side effects become too severe, or the patient or doctor decides to stop. Throughout the study, doctors will check how the tumors respond to treatment using scans and physical examinations. Patients will also have blood tests and other assessments to monitor their health and any side effects from the treatment.

To participate in this study, patients must have melanoma at an advanced stage with tumors that can be injected with the experimental medicines. They must have previously received treatment with drugs that block a protein called PD-1 or PD-L1, and their cancer must have either not responded to this treatment or started growing again during or shortly after such treatment. Patients with certain genetic changes in their cancer called BRAF mutations should have already tried or declined specific targeted treatments before receiving the PD-1 blocking drugs. The study requires that patients have recovered from any severe side effects from their previous treatments and have adequate organ function to safely receive the study medications.

The purpose of the study is to understand how safe and tolerable DYP688 is for patients and to see how well it works against these cancers. The study is divided into two phases. In the first phase, researchers will focus on determining the best dose of DYP688 and observing any side effects. In the second phase, they will evaluate how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive DYP688 and will be monitored closely by the research team. This includes regular check-ups and tests to track their health and the cancer’s response to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of DYP688. The study aims to gather important information that could lead to better treatment options for patients with these types of cancers in the future.

The purpose of the study is to evaluate how effective these treatments are in improving the condition of patients with these skin cancers. The study will involve administering the treatments over a period of up to four weeks. Patients will receive the treatment directly into their tumors, and the response of the tumors to the treatment will be monitored. The study aims to see if the tumors shrink or disappear and to assess the overall response rate of the treatment.

Throughout the study, the safety of the treatments will also be closely monitored. The study will help determine if these treatments can be a beneficial option for patients with skin cancers that are suitable for this type of direct tumor treatment. The results will provide valuable information on the potential of Darleukin and Fibromun in treating these specific types of skin cancer.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The goal of this study is to continue providing the treatment to patients who have already participated in earlier phases of similar studies but still need ongoing therapy since they cannot access these medicines locally. This means the therapy will continue for patients who are still benefiting from it according to assessments by their doctors.

The study does not provide detailed procedures but involves using these medicines to see if the patients continue to respond positively to the treatment therapies. This ongoing treatment will allow the observation of the treatments’ effects over a longer period and help determine the best use of these drugs in managing cancer. Some patients might be given a placebo, which is a substance with no therapeutic effect used in trials to test the effectiveness of another drug.

The research aims to understand how a specially labeled version of ipilimumab (marked with 89Zirconium) is taken up by tumor sites and other tissues in the body. The medication is given through intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The labeled medication allows researchers to track where the drug goes in the body and how it interacts with cancer cells.

During the study, participants will receive combination treatment with both ipilimumab and nivolumab. The study involves taking pictures of the body to see where the labeled medication collects. These images help researchers understand how the medication works in patients with metastatic melanoma. The maximum treatment period with the study medication is 3 months, with a maximum daily dose of 10 mg and a total maximum dose of 40 mg.

Participants in the study will receive Balstilimab and will be monitored over a period of time to assess the safety and effectiveness of the treatment. The study will look at how well the cancer responds to the treatment, whether it remains stable, shrinks, or disappears. The study will also track how long any positive effects last and monitor any side effects that may occur. Patients will have regular check-ups and tests to see how the treatment is affecting their health and the cancer.

The study aims to gather information on the overall survival rates of patients at 12 and 24 months after starting the treatment. It will also collect data on any changes in patients’ quality of life and general health. This information will help researchers understand if Balstilimab can be a beneficial treatment option for people with advanced non-melanoma skin cancers.